| Literature DB >> 28099427 |
Anglina Kataria1, Dov Levine1, Sara Wertenteil1, Suzanne Vento1, Jingchuan Xue2, Karthikraj Rajendiran2, Kurunthachalam Kannan2, Joshua M Thurman3, Debra Morrison4, Rachel Brody4, Elaine Urbina5, Teresa Attina1, Leonardo Trasande1, Howard Trachtman1.
Abstract
BACKGROUND: The health effects of bisphenol A (BPA) and di-(2-ethylhexyl) phthalate (DEHP) have been studied extensively in children. The impact of other chemicals in these two classes has not been investigated as fully.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28099427 PMCID: PMC5618435 DOI: 10.1038/pr.2017.16
Source DB: PubMed Journal: Pediatr Res ISSN: 0031-3998 Impact factor: 3.756
Categorization of Phthalate metabolites
| Phthalate parent compound | Metabolite | Category |
|---|---|---|
| Dimethyl phthalate | Monomethylphthalate (MMP) | LMW |
| Diethyl phthalate | Monoethylphthalate (MEP) | LMW |
| Di- | Mono-n-butylphthalate (MBP) | LMW |
| Mono-isobutylphthalate (MiBP) | LMW | |
| Di- | Mono-n-butylphthalate (MBP) | LMW |
| Butyl benzyl phthalate | Monobenzyl phthalate (MBzP) | HMW |
| Di-cyclohexylphthalate (DCHP) | Monocyclohexyl phthalate (MCHP) | HMW |
| Di-n-octyl phthalate | Monooctylphthalate (MOP) | HMW |
| Mono(3-carboxypropyl) phthalate (MCPP) | ||
| Di-isodecylphthalate (DIDP) | mono-(8-methyl-1-nonyl) phthalate (MIDP) | DIDP (also HMW) |
| Monocarboxyisononyl phthalate (MCNP) | ||
| Di-isononylphthalate (DINP) | Mono(3-carboxypropyl) phthalate (MCPP) | DINP (also HMW) |
| Monoisononyl phthalate (MNP) | ||
| Mono-(8-methyl-1-nonyl) phthalate (MIDP) | ||
| Monocarboxyisooctyl phthalate (MCOP) | ||
| Di-2-ethylhexyl phthalate (DEHP) | Mono(2-ethylhexyl) phthalate (MEHP) | DEHP (also HMW) |
| Mono-(2-ethyl-5-carboxypentyl) phthalate (MECPP) | ||
| Mono-(2-ethyl-5-hydroxyhexyl) phthalate (MEHHP) | ||
| Mono-(2-ethyl-5-oxohexyl) phthalate (MEOHP) | ||
| Mono-[(2-carboxymethyl) hexyl] phthalate (MCMHP) | ||
| Mono-hexylphthalate (MHxP) | Mono-hexylphthalate (MHxP) | HMW |
| Mono-2-heptyl phthalate (MHpP) | Mono-2-heptyl phthalate (MHpP) | HMW |
Summary of Study Participant Characteristics (N=41)
| Characteristic | Number (%) |
|---|---|
| Sex | |
| Male, n (%) | 19 (46%) |
| Female, n (%) | 22 (54.%) |
| Mean Age (SE) | 12.1 (0.2) |
| Race, n (%) | |
| Mexican American | 17 (42.%) |
| Other Hispanics | 14 (34.%) |
| Non-Hispanic White | 7 (17.%) |
| Non-Hispanic Black | 0 (0%) |
| Other | 3 (7.%) |
| Mean Fasting Glucose (SE) | 81.1 (1.6) |
| Mean Fasting Insulin (SE) | 10.2 (0.9) |
| Mean HOMA-IR (SE) | 2.1 (0.2) |
| Low socioeconomic status, n (%)* | 31 (76.%) |
| Overweight | 17 (42 %) |
| Obese | 9 (22. %) |
| Insulin Resistant | 8 (20%) |
| BP ≥ 90th percentile | 10 (24%) |
SE: standard error. Overweight and obese were categorized as BMI Z-score ≥1.036 and ≥1.64. Participants attending public school and receiving free lunches were categorized in the low socioeconomic category.
Median and interquartile range (IQR) of urinary concentrations of phenols and phthalates in the study population
| Chemical | Median (ng/mL) | IQR (ng/mL) |
|---|---|---|
| BPA | 0.23 | 0.141–1.16 |
| BPS | 2.06 | 1.56–2.69 |
| BPF | 0.141 | 0.141–0.141 |
| Total bisphenols | 2.98 | 2.41–4.42 |
| LMW phthalates | 0.55 | 0.41–0.86 |
| HMW phthalates | 0.36 | 0.24–0.55 |
| DEHP metabolites | 0.21 | 0.15–0.31 |
| DIDP metabolites | 0.0010 | 0.0006–0.0011 |
| DINP metabolites | 0.047 | 0.034–0.100 |
Comparison of Oxidant Stress, Endothelial Dysfunction Markers, and Insulin Resistance by Demographics, Anthropometric and Clinical Characteristics
| N | F2-isoprostane (ng/mL) | 8-OHdG (ng/mL) | HOMAIR | CD31+ 44 (% per mL) | CD 144+ 63e+ (% per mL) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sex | P-value | P-value | P-value | P-value | P-value | ||||||
| Male | 19 | 28.8 | 0.683 | 90.0 | 0.52 | 0.766 | 5.15 | 0.205 | 0.38 | 0.129 | |
| Female | 21 | 31.1 | 129.3 | 0.58 | 11.2 | 0.28 | |||||
| Age group, yr | |||||||||||
| 9–11 | 8 | 40.9 | 0.046 | 107.7 | 0.885 | 027 | 0.147 | 8.30 | 0.975 | 0.26 | 0.321 |
| 12–14 | 33 | 27.3 | 11.5 | 0.62 | 8.49 | 0.34 | |||||
| Race | |||||||||||
| Mexican American | 16 | 32.8 | Ref | 87.3 | Ref | 0.80 | Ref | 7.67 | Ref | 0.24 | Ref |
| Other Hispanics | 14 | 30.0 | 0.675 | 110.0 | 0.882 | 0.26 | 6.15 | 0.785 | 0.43 | ||
| Non-Hispanic White | 7 | 28.8 | 0.620 | 169.1 | 0.49 | 0.246 | 15.3 | 0.269 | 0.270 | .684 | |
| Other | 3 | 18.3 | 0.199 | 121.0 | 0.973 | 0.71 | 0.803 | 7.45 | 0.982 | 0.440 | .480 |
| Low SES | |||||||||||
| No | 10 | 35.0 | 0.364 | 134.2 | 0.56 | 0.972 | 14.4 | 0.193 | 0.32 | 0.883 | |
| Yes | 30 | 29.0 | 99.4 | 0.56 | 6.92 | 0.33 | |||||
| Overweight | |||||||||||
| No | 23 | 24.7 | 122.8 | 0.192 | 0.34 | 9.77 | 0.499 | 0.35 | 0.402 | ||
| Ye | 17 | 37.2 | 95.7 | 0.84 | 6.49 | 0.29 | |||||
| Obese | |||||||||||
| No | 31 | 29.6 | 0.804 | 111.3 | 0.913 | 0.4 | 7.84 | 0.605 | 0.35 | 0.129 | |
| Yes | 9 | 31.3 | 108.6 | 1.1 | 10.9 | 0.23 | |||||
| BP ≥ 90th percentile | |||||||||||
| No | 29 | 30.5 | 0.590 | 120.0 | 0.129 | 0.50 | 0.169 | 9.79 | 0.386 | 0.30 | 0.293 |
| Yes | 10 | 27 | 84.4 | 0.80 | 4.79 | 0.38 |
Multivariate Linear Regression Analysis of Oxidant Stress with Urinary Bisphenols and Phthalate metabolites
| Bisphenols | 8-OHdG,ng/mL, (CI) | F2-isoprostane ,ng/mL, (CI) |
|---|---|---|
| Bisphenol A | 6.74 (−30.47, 43.96) | 10.84 (1.819, 19.86)* |
| Bisphenol S | −114.56 (−305.0, 75.85) | −2.56 (−54.78, 49.67) |
| Bisphenol F | −9.27 (−84.20, 65.67) | 8.51 (−11.24, 28.25) |
| Total Bisphenols | −14.45 (−82.47, 53.56) | 11.50 (−6.30, 20.31) |
| DEHP Metabolites | −12.33 (−70.27, 45.61) | 14.48(−0.085, 29.04) |
| DIDP Metabolites | 3.81 (−24.26, 31.88) | −1.77 (−8.80, 5.28) |
| DINP Metabolites | −17.90 (−49.40, 13.60) | −1.03 (−8.44, 6.39) |
| LMW phthalates | −12.21 (−54.0, 29.57) | −3.42 (−14.65, 7.82) |
| HMW phthalates | −16.59 (−73.19, 40.02) | 5.75 (−8.796, 20.30) |
CI, confidence interval; .
All models were adjusted for age, sex, BMI z-score, total caloric intake and categorical physical activity
Multivariate Regression Analysis of Overweight, BMI, Insulin Resistance, Albumin to Creatinine Ratio and Brachial Artery Distensibility Outcomes Significantly Associated with Urinary Phthalate Metabolites and Phenols
| Overweight – Odds ratio (CI) | BMI (CI) | HOMA-IR (CI) | Brachial Artery Distensibility (CI) | A:C Ratio (CI) | CD 144+ 63e+, % per mL (CI) | |
|---|---|---|---|---|---|---|
| Bisphenol S | 3.750 (0.180, 7.320)* | −0.73 (−1.34, −0.12)* | ||||
| DEHP Metabolites | −0.743 (−1.475, −0.010)* | |||||
| HMW phthalates | 11.03 (1.303, 93.34)* | 4.335 (0.200, 8.470)* | 0.550 (0.973, 1.003)* | −0.20 (−0.37, −0.03)* |
A:C ratio, albumin-creatinine ratio; CI, confidence interval.
All models adjusted for age, sex, total caloric intake and categorical physical activity and BMI-z score (except when the outcome examined was overweight/BMI).